https://pepsreview.com/articles/ascletis-asc30-oral-glp1-phase-2-diabetes-endpoint PepsReview en 2026-10-31 ASC30, Ascletis, oral GLP-1, type 2 diabetes trial, small molecule GLP-1, Phase II results, GLP-1 obesity pipeline https://pepsreview.com/articles/fda-death-reports-two-cardiac-arrests-bootleg-retatrutide PepsReview en 2026-10-31 retatrutide deaths, bootleg retatrutide, FDA adverse event reports, FAERS, black market peptides, compounded retatrutide, retatrutide safety, unapproved GLP-1 https://pepsreview.com/articles/gray-market-retatrutide-reddit-symptom-study-jama-network-open PepsReview en 2026-10-30 retatrutide gray market, gray market peptides, retatrutide side effects, JAMA Network Open, peptide safety, unapproved GLP-1, Reddit drug reports https://pepsreview.com/articles/compounded-tirzepatide-b12-analogue-nebraska-jama-study PepsReview en 2026-10-30 compounded tirzepatide, compounded semaglutide, vitamin B12 analogue, levocarnitine, gray market GLP-1, compounding pharmacy, peptide purity, JAMA study